<DOC>
	<DOCNO>NCT02471469</DOCNO>
	<brief_summary>The primary aim show whether reduction tumor relate mRNAs panel select miRNAS use personalize enzalutamide therapy . Furthermore aim explore relation drug exposure decrease select biomarkers treatment response .</brief_summary>
	<brief_title>Personalizing Enzalutamide Therapy Understanding Relation Between Tumor mRNAs , miRNAs Treatment Response</brief_title>
	<detailed_description />
	<criteria>Male patient chemotherapy naive metastatic castration resistant prostate cancer* Age least 18 year Patients possible collect blood sample Patient able willing give write informed consent prior screen enrollment Life expectancy &gt; 6 month Measurable disease *definition CRPC accord EAU guideline 2014 None The study objective explore effect enzalutamide biomarker exposure group patient treat enzalutamide agreement drug label . Therefore strict exclusion criterion use study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>